A Look At Abbott’s Citizen Petition Against The Biologics Price Competition And Innovation Act

When the Supreme Court upheld the constitutionality of the Patient Protection and Affordable Care Act, those hoping to benefit from the portion of the law known as the Biologics Price Competition and Innovation Act (the “Biologics Act”) may have breathed a sigh of relief. However, the Biologics Act is not out of the woods, because Abbott recently filed a Citizen Petition with the FDA, seeking to block its implementation of the law as unconstitutional.

The Biologics Act

The Biologics Act creates a path to market entry for biological products that is similar to (but substantially different from) the path provided to small molecule drugs by the Drug Price Competition and Patent Term Restoration Act of 1984 (generally known as the “Hatch-Waxman Act”). (A copy of the law is available through the FDA’s Biosimilars webpage.) Key differences in the regulatory approval provisions of the Biologics Act reflect the complex nature of biologics and the safety and efficacy concerns surrounding biological products that may not be chemically identical to the approved reference product. The Biologics Act also has a completely different mechanism for treating patent issues than those set forth in the Hatch-Waxman Act. (This article provides a more detailed discussion of the Biologics Act.)

Like the Hatch-Waxman Act, the Biosimilars Act arose from a desire to facilitate market entry of lower-cost “generic” versions of biological drugs. For example, at the Biosimilars 2007 Conference, Representative Henry Waxman remarked that “biotech drugs are the future of medicine.” In 2006, the last year for which data is available, biotech sales grew by 20% to $40.3 billion, while sales of traditional, small molecule pharmaceuticals increased by only 8%. With skyrocketing pharmaceutical costs and increased consumer demand, lower-cost alternatives are understandably a priority. However, the demand for “generic” versions of biologics must not take precedence over the need to ensure the safety and efficacy of approved pharmaceutical products and must be balanced against the need for sufficient market exclusivity for innovator products to incentivize continued research and development.

The Biologics Act attempts to balance these competing interests by providing timeframes of exclusivity to innovator (reference) biologic drug products. For example, an application for FDA approval of a biosimilar product can be filed four years after approval of the reference product, but the application may not be approved until 12 years after approval of the reference product. (Approval of a biosimilar may be further delayed if patent infringement claims are still pending.)

Abbott’s Citizen Petition

Abbott Laboratories filed a Citizen Petition with the FDA on April 2, 2012, asserting that if the FDA approves a biosimilar of its Humira® product under the Biologics Act, the agency will be engaging in an unconstitutional taking of the company’s intellectual property. Specifically, Abbott argues that much of the analytical, preclinical, clinical, and manufacturing data and information from Abbott’s extensive testing and development of Humira® is eligible for trade secret protection and may not be relied upon by the FDA to support a biosimilar application of a third party. Abbott asks that the FDA not consider any application that cites Humira® as a reference product. (Abbott’s main patent on Humira® is set to expire in December 2016).

Abbott’s petition follows that of Genentech filed in 2004. Genentech asserted that the agency should not even issue a guidance document relating to the data requirements for biosimilar applications, since such guidance would benefit from knowledge gleaned from patentees such as Genentech. The FDA ultimately denied the Genentech petition, stating that the guidance did not “violate any protections available to applicants by relying, either ‘directly or indirectly,’ on Genentech’s or any other entity’s confidential information. . . [,] [did] not disclose any trade secret or confidential information, and [that] FDA did not impermissibly use or rely upon any such information in developing them.” (See this article for an overview of the FDA’s draft guidance document.) Abbott’s petition raises a harder question, because a biosimilar application would, by definition, rely upon the data supplied by the reference sponsor.

A Long Road Ahead

It is likely that the issues raised in Abbott’s Citizen Petition ultimately will have to be decided by the courts. The final outcome could impact the viability of the biosimilar framework, and have far-reaching effects on the biotechnology industry, as well as on healthcare costs and patient care. As the U.S. struggles with these issues, it is interesting to watch how they have played out in other countries. For example, the European Union’s EMA has had a biosimilar approval process since 2003, and fourteen biosimilar products have been approved to date. While parties on either side of the Patient Protection and Affordable Care Act debate whether we should have a European-style healthcare system, parties on either side of the Biologics Act may debate whether we should have an EMA-type biosimilars system.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

"My best business intelligence, in one easy email…"

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.

Privacy Policy (Updated: October 8, 2015):

hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.